pharmaceutical investing Menlo Therapeutics Announces Results from a Phase 2 Trial of Serlopitant for Pruritus Associated with Atopic Dermatitis
pharmaceutical investing Menlo Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results
AnaptysBio Announces Positive Top-Line Proof-of-Concept Data For ANB020 In Moderate-to-Severe Baseline
pharmaceutical investing Sienna Biopharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results
pharmaceutical investing Dermira’s Share Price Takes a Hit as Two Clinical Trials Failed to Meet Co-Primary Endpoints
Dermira Initiates Phase 2b Dose-Ranging Study Evaluating Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis
pharmaceutical investing Immune Pharmaceuticals Announces the launch of REMAIN ™ , an international Overall Survival study with Ceplene® and low dose Proleukin® in REmission MAINtenance in Acute Myeloid Leukemia
Prismo Metals Announces Closing of Upsized Private Placement Silver King Exploration to Begin in July
